Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:0e85cbe13a5e2f7bad5dca800472c228] - Clinical Trials - bio2rdf - TriplyDB

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:0e85cbe13a5e2f7bad5dca800472c228]

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:0e85cbe13a5e2f7bad5dca800472c228]

AE = Adverse event ECG = Electrocardiogram

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]

http://bio2rdf.org/clinicaltrials_resource:0e85cbe13a5e2f7bad5dca800472c228

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:0e85cbe13a5e2f7bad5dca800472c228]

Bio2RDF uri

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects [clinicaltrials:NCT02079480]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:0e85cbe13a5e2f7bad5dca800472c228]

AE = Adverse event ECG = Electrocardiogram

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]

http://bio2rdf.org/clinicaltrials_resource:0e85cbe13a5e2f7bad5dca800472c228

Bio2RDF identifier

0e85cbe13a5e2f7bad5dca800472c228

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials_resource

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials_resource:0e85cbe13a5e2f7bad5dca800472c228

http://www.w3.org/2001/XMLSchema#string

measure [clinicaltrials_vocabulary:measure]

Safety and tolerability of sin ...... amination and laboratory tests

http://www.w3.org/2001/XMLSchema#string

time frame [clinicaltrials_vocabulary:time-frame]

Up to Day 85 after single dose of BMS-986090

http://www.w3.org/2001/XMLSchema#string

description

AE = Adverse event ECG = Electrocardiogram

http://www.w3.org/2001/XMLSchema#string

identifier

clinicaltrials_resource:0e85cbe13a5e2f7bad5dca800472c228

http://www.w3.org/2001/XMLSchema#string

title

Safety and tolerability of sin ...... fter single dose of BMS-986090

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]

label

Safety and tolerability of sin ...... 5cbe13a5e2f7bad5dca800472c228]

@en